Skip to main navigation

Live - Top Menu

  • Clinical Trials
  • Investors & Media
  • Careers
  • Contact Us
Menu
Close

Main navigation

  • Our Focus
  • Our Research
  • Our Medicine
  • Our Story
Home > Investors & Media > Press Releases
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Leadership
      • Board of Directors
    • Financial Information
      • SEC Filings
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
      • Dividend History
      • Analyst Coverage
    • Contact Us

Shareholder Tools

  • Email Alerts
  • Download Library
  • RSS
  • Print
  • Share
  • Facebook
  • LinkedIn
  • Twitter

Press Releases

Press Releases

May 11, 2022
Intercept Announces First Patient Dosed in Phase 2 Study of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis
Additional Phase 2 trial of the OCA-bezafibrate combination remains ongoing in Europe MORRISTOWN, N.J. , May 11, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat
Read More
May 06, 2022
Intercept Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
Worldwide Ocaliva ® net sales of $88.6 million , representing 8% growth over the prior year quarter Nearing completion of new REGENERATE data analyses; planning for potential pre-submission meeting with FDA in June Continue to expect topline results from Phase 3 REVERSE study in compensated
Read More
May 05, 2022
Intercept Announces Advanz Pharma to Acquire Ocaliva in PBC in Markets Outside the U.S. for up to $450MM, including $405MM Upfront and an Additional $45MM in Contingent Payments
Agreement includes rights for Advanz to commercialize orphan drug Ocaliva® for PBC outside the U.S. , as well as the transition to Advanz of the international commercial and medical infrastructure of Intercept Additionally, Intercept will receive royalties on any future ex- U.S.
Read More
May 02, 2022
Intercept to Announce First Quarter 2022 Financial Results on May 6, 2022
MORRISTOWN, N.J. , May 02, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals , Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2022 financial
Read More
Mar 02, 2022
Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results, Issues 2022 Financial Guidance and Provides Business Update
Worldwide Ocaliva® net sales of $92.4 million and $363.5 million for the fourth quarter and full year 2021, representing 11% and 16% growth over the prior year Company provides 2022 Ocaliva net sales guidance of $375 million to $405 million and non-GAAP adjusted operating expense guidance of $360
Read More
Feb 23, 2022
Intercept to Announce Fourth Quarter and Full Year 2021 Financial Results on March 2, 2022
NEW YORK , Feb. 23, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals , Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its fourth quarter and full year 2021
Read More
Dec 20, 2021
Intercept Pharmaceuticals Provides Update on Phase 3 REVERSE Trial in Compensated Cirrhosis Due to NASH
Study remains ongoing; top-line data anticipated in Q1 2022 versus near the end of the year NEW YORK , Dec. 20, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals , Inc. (NASDAQ: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat
Read More
Dec 09, 2021
Intercept Announces Withdrawal of EMA Marketing Authorization Application for Obeticholic Acid for Advanced Liver Fibrosis Due to NASH
NEW YORK , Dec. 09, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has formally notified the European
Read More
Nov 15, 2021
Intercept Announces New Long-Term Data Demonstrating Potential of Obeticholic Acid to Improve Transplant-Free Survival in Patients with PBC
Analysis compares findings from the long-term safety extension of the Phase 3 POISE trial to PBC natural history data from the Global PBC and UK -PBC databases Results will be featured in a late-breaking podium presentation at The Liver Meeting ® NEW YORK , Nov.
Read More
Nov 11, 2021
Intercept to Present at Upcoming Investor Conferences
NEW YORK , Nov. 11, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals , Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief
Read More

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Current page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page next ›
  • Last page last »
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Leadership
      • Board of Directors
    • Financial Information
      • SEC Filings
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
      • Dividend History
      • Analyst Coverage
    • Contact Us

Shareholder Tools

  • Email Alerts
  • Download Library
  • RSS
  • Print
  • Share
  • Facebook
  • LinkedIn
  • Twitter

Live - Footer Menu

  • Privacy Policy
  • Privacy Shield Policy
  • Corporate Compliance
  • Terms of Use
  • Contact Us
  • Cookie Preferences
305 Madison Avenue|Morristown, NJ 07960|T: 844-782-ICPT
© 2023 Intercept Pharmaceuticals, Inc.